Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

Table 2 Univariate analysis of predictors for OS and PFS

Clinical variable		mOS (months)	Log Rank test, P	mPFS (months)	Log Rank test, P
Gender	Male	24.0	0.413	11.0	0.131
Gender	Female	23.0		10.0
Age	<65 years	24.0	0.714	10.6	0.435
Age	≥65 years	24.0		11.0
Pathology	Clear cell type	25.5	<0.001	11.3	<0.001
Pathology	Non-clear cell type	14.0		7.0
ECOG	0	30.0	<0.001	12.1	<0.001
	1	22.1		10.6
	2	11.0		5.9
	3	8.8		3.4
Previous nephrectomy	Yes	26.7	<0.001	11.6	<0.001
Previous nephrectomy	No	14.0		7.0
MSKCC	Low risk	39.0	<0.001	15.0	<0.001
	Moderate risk	22.0		9.5
	High risk	9.3		5.2
HENG	Low risk	39.0	<0.001	15.0	<0.001
	Moderate risk	22.0		9.4
	High risk	10.3		5.8
Number of metastatic organs	1	32.0	<0.001	14.0	<0.001
	2	21.0		9.6
	3	15.3		8.0
	4	16.0		7.0
Lung metastasis	No	23.0	0.362	10.0	0.429
Lung metastasis	Yes	24.0		11.0
Simple lung metastasis	No	21.4	<0.001	9.3	<0.001
Simple lung metastasis	Yes	32.4		15.0
Bone metastasis	No	26.0	<0.001	12.0	0.001
Bone metastasis	Yes	20.4		9.0
Simple bone metastasis	No	24.0	0.182	10.5	0.016
Simple bone metastasis	Yes	24.0		12.0
Liver metastasis	No	25.0	<0.001	11.3	<0.001
Liver metastasis	Yes	15.0		6.0
Lymph node metastasis	No	27.5	<0.001	12.0	<0.001
Lymph node metastasis	Yes	18.0		9.0
RECIST response	CR	60.0	<0.001	31.5	<0.001
	PR	36.0		20.7
	SD	23.3		10.4
	PD	8.3		3.0
Second line treatment	Yes	30.0	0.024	10.9	0.363
Second line treatment	No	22.0		10.5

ECOG eastern cooperative oncology group, MSKCC memorial sloan-kettering cancer centre, OS overall survival, PFS progression-free survival

ISSN: 1471-2407